Kratom and kava marketing carries FDA and DEA risk. FDA says 7-hydroxymitragynine (7-OH) is not lawful in dietary supplements or conventional foods, and DEA announced on October 14, 2026 that it intends to place 7-OH above a threshold in Schedule I, no earlier than November 13, 2026. FDA has also warned since 2002 that kava supplements may be linked to severe liver injury.
This guide is communications research, not legal advice. State laws on kratom vary widely and are not covered in detail here. Last verified October 16, 2026.
What has FDA said about kratom marketing?
FDA says 7-OH is not lawful in dietary supplements and cannot be lawfully added to conventional foods. In its announcement of seven warning letters, the agency also said there are no FDA-approved drugs containing 7-OH, and that it is illegal to market any drug containing it. The letters went to companies selling concentrated 7-OH as tablets, gummies, drink mixes and shots.
FDA noted that 7-OH occurs naturally in trace amounts in kratom, and that its letters focus on concentrated 7-OH products and products with added or enhanced 7-OH. In late July 2025, HHS recommended Schedule I control of 7-OH, according to DEA's later Federal Register notice.
What has DEA done about kratom and 7-OH?
DEA has acted on related compounds and has announced its intent to schedule 7-OH above a threshold. Its October 14, 2026 notice of intent in the Federal Register says HHS sent a new recommendation on October 8, 2026 to control 7-OH and mitragynine pseudoindoxyl in Schedule I when they exceed a specified threshold.
The notice says the temporary scheduling order will be published on or after November 13, 2026. It also says DEA placed mitragynine pseudoindoxyl in Schedule I by temporary order on August 26, 2026, and that neither HHS nor DEA has found these substances safe at below-threshold levels. Until the 7-OH order is published, 7-OH is not federally scheduled, so brands should plan for the change.
What has FDA said about kava marketing?
FDA has warned since 2002 that kava supplements may be associated with severe liver injury. On March 25, 2002, FDA issued a consumer advisory after reports of liver-related injuries, including hepatitis, cirrhosis and liver failure, according to the NIH Office of Dietary Supplements. The CDC's MMWR report notes kava products were then sold as supplements for anxiety, occasional insomnia, premenstrual syndrome and stress.
The advisory also says FDA has not determined whether kava supplements provide those benefits. A brand that makes anxiety or sleep claims for kava is making claims the agency has declined to confirm.
What can kratom and kava brands safely communicate?
Brands in these categories should communicate product facts and compliance, not health outcomes. Treat the following as EPR guidance and have counsel review it.
Do
Avoid
State plainly what the product is, its source and its testing
Claims that a product treats anxiety, pain, opioid withdrawal or other conditions
Use third-party lab results for contaminants and alkaloid content
Marketing concentrated or synthetic 7-OH as a supplement
Age-gate owned channels and follow state sales rules
Imagery or influencers that appeal to minors
Cite FDA's own warnings accurately where relevant
Implying FDA has approved or endorsed kratom or kava
What do Google and Meta ad policies say about kratom and kava?
Both platforms give themselves wide discretion over supplement ads, so kratom and kava ads can be rejected even where the product is legal. Meta's unsafe supplements policy bars ads that promote the sale or use of illicit or recreational drugs or other unsafe substances, products or supplements, as determined by Meta at its sole discretion.
Google's healthcare and medicines policy for Shopping ads restricts unapproved pharmaceuticals and supplements, including herbal and dietary supplements with active pharmaceutical or dangerous ingredients. Review the current policy for each platform and product before building a campaign.
Why does kratom marketing carry reputation risk?
Kratom marketing carries reputation risk because FDA treats concentrated 7-OH products as unlawful and DEA has paired enforcement with a scheduling process. Industry groups have drawn the same line. The American Herbal Products Association says it advises against synthesized 7-OH in any consumable product and promotes responsible marketing of kratom leaf. Brands that blur the line between leaf and concentrates invite both regulator and press attention.
FDA says 7-OH is not lawful in dietary supplements or conventional foods. DEA intends to place 7-OH above a threshold in Schedule I by temporary order no earlier than November 13, 2026. State laws vary, so check each state before marketing.
Is 7-OH a controlled substance yet?
Not yet. DEA's October 14, 2026 notice says the temporary order will be published on or after November 13, 2026. DEA did schedule mitragynine pseudoindoxyl by temporary order on August 26, 2026.
What did FDA do about 7-OH in 2025?
FDA announced warning letters to seven companies marketing concentrated 7-OH products, and HHS recommended Schedule I control of 7-OH in late July 2025.
Is kava safe to market for anxiety?
FDA's 2002 advisory warns of a risk of severe liver injury and says the agency has not determined that kava supplements provide benefits such as relief from anxiety.
Can kratom or kava brands advertise on Google and Meta?
Meta bars ads for unsafe substances, products or supplements at its sole discretion, and Google restricts unapproved supplements and herbal supplements with dangerous ingredients. Confirm each platform's current policy before running ads. Sources: FDA, the Federal Register, NIH, CDC, Meta and Google policy pages, checked October 16, 2026.
Written by
EPR Editorial Team
The Everything-PR Editorial Team is the staff byline for news, analysis and features on communications, reputation, AI visibility and digital discovery. Everything-PR has published since 2009. AI tools assist with research and drafting, and every article is reviewed by a human editor before publication. Coverage follows the Editorial Policy, and substantive corrections are noted on the article under the Corrections Policy.
